Moderna Therapeutics and Merck have entered a license and collaboration agreement for the discovery and development of vaccines and passive immunity treatments against viral diseases using Moderna’s modified messenger RNA (mRNA) expertise. Moderna’s efforts will be led by Valera, its venture focused on the development of mRNA vaccines and therapeutics to fight infectious disease. Preclinical research at Moderna shows the ability of modified mRNA to express viral antigens in vivo and to ind...